CervoMed宣布,公司计划在2026年路易体痴呆协会年度会议上,详细介绍其核心候选药物Neflamapimod的临床研发项目最新数据与进展。此外,CervoMed的研究专家还将受邀参与一场关于生物标志物的专题小组讨论,分享在该领域的见解与发现。
CervoMed宣布,公司计划在2026年路易体痴呆协会年度会议上,详细介绍其核心候选药物Neflamapimod的临床研发项目最新数据与进展。此外,CervoMed的研究专家还将受邀参与一场关于生物标志物的专题小组讨论,分享在该领域的见解与发现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.